Inflarx Stock Price, News & Analysis

InflaRx reported positive developments for vilobelimab, focusing on treatment for Hidradenitis Suppurativa (HS) and Pyoderma Gangraenosum (PG). The FDA endorsed a new primary endpoint for HS, while in PG, 6 of 7 patients achieved clinical remission in a Phase IIa study. The company secured a €43.7 million grant from the German government to advance vilobelimab for severe COVID-19. As of September 30, 2021, InflaRx had approximately €120.6 million in cash and equivalents, despite a net loss of €33 million for the nine months ended. Topline COVID-19 data is expected in Q1 2022.

InflaRx (Nasdaq: IFRX) announced that Prof. Niels C. Riedemann, CEO and Founder, will present a corporate overview during a fireside chat at the Credit Suisse 30th Annual Healthcare Conference. The session is scheduled for November 10, at 9:40 am EST/3:40 pm CET, and will be accessible via a live webcast on the InflaRx website. InflaRx focuses on developing anti-inflammatory therapeutics by targeting the complement system, specifically inhibitors of C5a, which is crucial in autoimmune and inflammatory diseases.

InflaRx N.V. (Nasdaq: IFRX) announced promising results from its Phase IIa study of vilobelimab for Pyoderma Gangraenosum (PG). In the highest dose cohort, 85.7% of patients demonstrated clinical remission, with no dose-related adverse events reported. The study enrolled 19 patients, showing significant efficacy at various dosages. InflaRx plans to seek FDA guidance for a pivotal program based on these results. A conference call will be held today at 8:30 am EDT to discuss this data further.

InflaRx N.V. (Nasdaq: IFRX) has been awarded a grant of up to EUR 43.7 million by the German government to support the development of vilobelimab for COVID-19 treatment. The initial tranche of EUR 25.8 million will reimburse 80% of specified expenses related to clinical development and manufacturing. The grant aims to expedite vilobelimab's development and secure manufacturing capacity in Germany. The ongoing Phase III study is fully enrolled, with top-line results expected in Q1 2022.

InflaRx N.V. (Nasdaq: IFRX) has completed enrollment in the Phase III portion of its vilobelimab study, which targets severe COVID-19 patients. The study enrolled 369 patients in multiple countries, including Europe and South America. Topline results are anticipated in Q1 2022, focusing on 28-day all-cause mortality among other endpoints. The Phase II part showed a mortality rate of 13% in the vilobelimab arm versus 27% in the control group. Vilobelimab is a promising anti-C5a antibody aimed at treating various inflammatory conditions.

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company, announces that CEO Prof. Niels C. Riedemann will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on demand from 7:00 AM EDT / 1:00 PM CET on September 13, 2021. A webcast of the event can be accessed for 90 days on the InflaRx website in the Investors section.

InflaRx focuses on developing anti-inflammatory therapeutics targeting the complement system, specifically through its proprietary anti-C5a technology.

InflaRx (Nasdaq: IFRX) has received FDA feedback from its Type A meeting, supporting a pivotal development program for vilobelimab in treating moderate to severe Hidradenitis Suppurativa (HS). The FDA acknowledged that targeting pain and draining lesions represents a clinically meaningful outcome, leading to a new primary efficacy endpoint. The company aims to submit the updated study protocol in Q4 2021, following FDA approval. With a significant need for new treatments, vilobelimab is positioned as a potential solution for HS patients suffering from debilitating symptoms.

InflaRx N.V. (Nasdaq: IFRX) announced encouraging results from its Phase IIa study of vilobelimab in Pyoderma Gangraenosum (PG), with four out of ten evaluable patients showing a clinical response at day 99. Three patients achieved complete closure of their target lesions, with treatment being well tolerated and no significant adverse events during dose escalation. The study enrolled 19 patients, with doses of vilobelimab ranging from 800mg to 2400mg. The ongoing study aims to assess vilobelimab's efficacy and safety further, especially in the higher dose cohort.

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company, will present at the BTIG Virtual Biotechnology Conference on August 10, 2021. The event will feature a fireside chat with CEO Prof. Niels C. Riedemann, discussing the company's pipeline and upcoming catalysts at 9:00 am EDT. InflaRx is focused on developing first-in-class inhibitors of C5a, a key inflammatory mediator involved in various autoimmune diseases. Founded in 2007, the company operates in Germany and the USA.